Thematic / Megatrends

Consider how global mega forces are impacting portfolios

Proof Pending: Can AI Deliver Lasting Growth?
  • 29 Jun 2026

AI spending is lifting growth now, but productivity must carry it forward. AI infrastructure spending is driving record equity market raisings and has lifted expectations for long-term GDP growth i...

Project Glasswing and Mythos: Redefining the cybersecurity landscape
  • 29 Jun 2026

Cybersecurity’s evolution into critical AI infrastructure.

Growth holds but inflation risks reshape outlook
  • 29 Jun 2026

Global growth steadies as inflation risks persist, with AI-driven demand, geopolitics, and policy uncertainty shaping outlooks across major economies and markets.

Is Your PE Playbook Still the Right One for the Current Cycle?
  • 29 Jun 2026

Key Takeaways Private equity portfolios built around large buyouts and co-investments may need rebalancing in an environment that increasingly rewards smaller companies with greater potential to g...

As the Playing Field Expands, Insurance Investors Must Stay Nimble
  • 29 Jun 2026

A holistic approach may help navigate the diverse, dynamic world of fixed-income opportunities.  Insurance investors face a broader opportunity set than ever across public and private credit—from c...

AI’s reality check reinforces diversification
  • 29 Jun 2026

South Korea has experienced strong market swings in recent weeks, as the AI trade has come under pressure at a global level.

UBP Weekly View - As energy fades, AI emerges as the new face of inflation
  • 29 Jun 2026

A fading energy shock drove developed market rates lower, even as US personal consumption expenditure (PCE) inflation surprised on the upside at 4.07% y/y, with artificial intelligence (AI)-related...

Inside China’s AI Boom
  • 29 Jun 2026

As China develops an increasingly independent AI ecosystem, new investment opportunities are emerging across software, semiconductors, and digital infrastructure.

Can AI Improve Drug Development? It Depends on the Data
  • 29 Jun 2026

Drug development is costly and often failure-prone. AI can help screen out weak candidates earlier, but only if the data is strong.